| 标题： | Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes. |
| 时间： | 2019-02-11 15:58:32 |
| DOI： | 10.1080/14712598.2018.1439014 |
| PMID： | 29431519 |
| 作者： | Maka S Hedrington;Ana Tsiskarishvili;Stephen N Davis |
| 出版源： | 《Expert Opinion on Biological Therapy》 ,2018 ,18 (3) |
| 摘要： | Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetesIntroduction: This manuscript describes 21 drug targets in the area of diabetes and related conditions that were discontinued in 2015. Areas covered: The material for this paper was obtained by contacting biopharmaceutical companies, reviewing their pipelines, press releases and annual reports. Additionally, ... |
| 大小： | 1195 kb |
| 页数： | 11 PAGES |
| 下载： | 点击下载 |
| 预览： |
目录：
- Abstract
- 1. Introduction
- 2. Structure and chemistry
- 3. Clinical development of semaglutide
- 3.1. Phase 1 trials
- 3.1.1. QTc
- 3.1.2. Drug interactions
- 3.1.3. Gastric emptying
- 3.2. Phase 2 trial
- 3.3. Phase 3 trials
- 3.4. Safety and tolerability
- 3.1. Phase 1 trials
- 4. Regulatory affairs
- 5. Expert opinion
- Declaration of interest
- References
本页内容由网络收集而来，版权归原创者所有，如有侵权请及时联系